Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperlipidaemia in diabetes.

M R Taskinen

    Bailliere'S Clinical Endocrinology and Metabolism
    |December 1, 1990
    PubMed
    Summary
    This summary is machine-generated.

    Diabetic patients need lower lipid targets for cardiovascular disease (CVD) risk. More clinical trials are essential to confirm the benefits of lipid-lowering therapies in diabetes mellitus.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Genetically determined increase in apolipoprotein C-III (APOC3 gain-of-function) delays very low-density lipoprotein clearance in humans.

    Atherosclerosis·2025
    Same author

    Acquired liver fat is a key determinant of serum lipid alterations in healthy monozygotic twins.

    Obesity (Silver Spring, Md.)·2013
    Same author

    Response letter to D. Singh-franco et al.

    Diabetes, obesity & metabolism·2012
    Same author

    Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study.

    Diabetologia·2011
    Same author

    Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance.

    Diabetologia·2007
    Same author

    Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

    Diabetologia·2007
    Same journal

    Phytoestrogen content in foods.

    Bailliere's clinical endocrinology and metabolism·1999
    Same journal

    Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data.

    Bailliere's clinical endocrinology and metabolism·1999
    Same journal

    Experimental studies on lignans and cancer.

    Bailliere's clinical endocrinology and metabolism·1999
    Same journal

    Reproductive actions of phytoestrogens.

    Bailliere's clinical endocrinology and metabolism·1999
    Same journal

    Phytoestrogens and inhibition of angiogenesis.

    Bailliere's clinical endocrinology and metabolism·1999
    Same journal

    Phytoestrogens and diseases of the prostate gland.

    Bailliere's clinical endocrinology and metabolism·1999
    See all related articles

    Area of Science:

    • Cardiology
    • Endocrinology
    • Metabolic Disorders

    Background:

    • Lipid abnormalities are significant risk factors for coronary heart disease (CHD) in diabetic populations.
    • Current understanding of specific lipid parameters and their predictive power for CHD in diabetes is insufficient.
    • Diabetic patients have a higher inherent risk of CHD, necessitating tailored therapeutic strategies.

    Purpose of the Study:

    • To identify quantitative and qualitative lipoprotein and apoprotein abnormalities signifying CHD risk in diabetes.
    • To define the predictive power of these abnormalities in prospective trials.
    • To establish optimal therapeutic strategies for lipid disorders in diabetic individuals.

    Main Methods:

    • Review of existing knowledge on lipid abnormalities and insulin action in diabetes.

    Related Experiment Videos

  • Analysis of typical lipid profiles in non-insulin-dependent diabetes mellitus (NIDDM), including hypertriglyceridemia and low HDL levels.
  • Emphasis on the need for prospective trials to evaluate lipid-lowering interventions.

    • Main Results:

    • Target lipid values for diabetic populations should likely be lower than those recommended for non-diabetic individuals.
    • No primary or secondary intervention trials in diabetic populations have definitively shown that lowering lipids reduces CHD morbidity or mortality.
    • Hypertriglyceridemia and low HDL cholesterol are characteristic of NIDDM, presenting a unique group for intervention studies.

    Conclusions:

    • There is a pressing need for clinical trials in both insulin-dependent diabetes mellitus (IDDM) and NIDDM.
    • These trials should provide adequate information on the benefits of lipid-lowering therapy.
    • Confirming treatment strategies for managing lipid disorders and reducing CHD risk in diabetes is crucial.